VistaGen expects to receive European patent for migraine drug, shares rise

Vistagen Therapeutics

13/06/2023 15:14

** Shares of drug developer VistaGen Therapeutics Inc
 VTGN.O  rise 2.5% to $2.49 
    ** VTGN says European Patent Office (EPO) issued an
intention to grant a patent for its experimental nasal spray to
treat migraine 
    ** The patent is expected to provide protection to the
experimental drug, PH80, until 2040
     ** The patent claims also include treatment administered at
the onset of migraine symptoms and treatment of migraines
associated with traumatic brain injury -VTGN 
    ** VTGN says it has also received a similar patent in the
U.S.
    ** Including session gains, stock down ~20% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))